Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ARGX – argenx SE

Float Short %

3.08

Margin Of Safety %

-19

Put/Call OI Ratio

0.32

EPS Next Q Diff

0.82

EPS Last/This Y

EPS This/Next Y

7.19

Price

660.23

Target Price

806.47

Analyst Recom

1.25

Performance Q

13.51

Relative Volume

0.57

Beta

0.41

Ticker: ARGX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25ARGX591.980.611.377979
2025-07-28ARGX595.030.610.077992
2025-07-29ARGX599.020.590.038245
2025-07-30ARGX598.910.540.248659
2025-07-31ARGX669.490.420.2110882
2025-08-01ARGX673.840.410.1211380
2025-08-04ARGX690.60.400.5611920
2025-08-05ARGX675.450.401.0212369
2025-08-06ARGX672.710.400.4912420
2025-08-07ARGX672.190.400.7412666
2025-08-08ARGX661.650.410.1612819
2025-08-11ARGX638.520.404.7512899
2025-08-12ARGX637.40.420.1813149
2025-08-13ARGX646.60.410.0913314
2025-08-14ARGX652.360.410.0313367
2025-08-15ARGX653.970.410.2513384
2025-08-18ARGX661.140.340.057956
2025-08-19ARGX657.120.322.318456
2025-08-20ARGX660.90.320.008494
2025-08-21ARGX663.790.310.528688
2025-08-22ARGX660.230.320.028744
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25ARGX591.99533.7-44.411.77
2025-07-28ARGX594.86530.6-53.811.77
2025-07-29ARGX598.79530.6-57.011.70
2025-07-30ARGX598.89530.6-58.011.70
2025-07-31ARGX670.33530.6-23.811.70
2025-08-01ARGX673.80130.5-21.511.51
2025-08-04ARGX690.32130.5-353.911.51
2025-08-05ARGX674.90130.5-369.511.51
2025-08-06ARGX672.99186.9102.413.30
2025-08-07ARGX672.35186.9125.713.35
2025-08-08ARGX661.83186.9121.913.35
2025-08-11ARGX638.83186.7102.513.35
2025-08-12ARGX637.41186.7124.413.35
2025-08-13ARGX646.60186.7153.913.35
2025-08-14ARGX652.69186.7163.913.35
2025-08-15ARGX653.83186.7157.713.35
2025-08-18ARGX661.13186.7172.913.35
2025-08-19ARGX656.89186.7134.813.35
2025-08-20ARGX660.90186.7163.313.34
2025-08-21ARGX663.03186.7159.613.34
2025-08-22ARGX660.23186.7135.613.34
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25ARGX0.00-2.492.94
2025-07-28ARGX0.00-2.552.94
2025-07-29ARGX0.00-2.552.94
2025-07-30ARGX0.00-2.552.94
2025-07-31ARGX0.00-2.552.94
2025-08-01ARGX0.00-2.552.94
2025-08-04ARGX0.00-2.592.94
2025-08-05ARGX0.00-2.592.94
2025-08-06ARGX0.00-2.592.94
2025-08-07ARGX0.00-2.592.94
2025-08-08ARGX0.00-2.592.94
2025-08-11ARGX0.00-2.532.94
2025-08-12ARGX0.00-2.533.08
2025-08-13ARGX0.00-2.533.08
2025-08-14ARGX0.00-2.533.08
2025-08-15ARGX0.00-2.533.08
2025-08-18ARGX0.0015.903.08
2025-08-19ARGX0.0015.903.08
2025-08-20ARGX0.0015.903.08
2025-08-21ARGX0.0015.903.08
2025-08-22ARGX0.0015.903.08
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

3.74

Avg. EPS Est. Current Quarter

3.67

Avg. EPS Est. Next Quarter

4.56

Insider Transactions

Institutional Transactions

15.9

Beta

0.41

Average Sales Estimate Current Quarter

921

Average Sales Estimate Next Quarter

1016

Fair Value

538.08

Quality Score

100

Growth Score

67

Sentiment Score

87

Actual DrawDown %

5.2

Max Drawdown 5-Year %

-38.2

Target Price

806.47

P/E

33.55

Forward P/E

27.32

PEG

0.91

P/S

13.19

P/B

6.62

P/Free Cash Flow

75.29

EPS

19.67

Average EPS Est. Cur. Y​

13.34

EPS Next Y. (Est.)

20.53

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

41.87

Relative Volume

0.57

Return on Equity vs Sector %

-13.6

Return on Equity vs Industry %

-0.7

EPS 1 7Days Diff

EPS 1 30Days Diff

1.29

EBIT Estimation

135.6
argenx SE
Sector: Healthcare
Industry: Biotechnology
Employees: 1599
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
stock quote shares ARGX – argenx SE Stock Price stock today
news today ARGX – argenx SE stock forecast ,stock prediction 2023 2024 2025
marketwatch ARGX – argenx SE yahoo finance google finance
stock history ARGX – argenx SE invest stock market
stock prices ARGX premarket after hours
ticker ARGX fair value insiders trading